Pharma

May 7 2018

PHARMACEUTICAL BRAND NAMING, BRAND INSTITUTE, PRODUCT NAME DEVELOPMENT SERVICES, GLOBAL BRANDING, BRANDING CONSULTANTS LOS ANGELES, NEW YORK, TORONTO, TOKYO, shionogi pharma.#Shionogi #pharma

Welcome to Brand Institute. We name more products than anyone in the world! Recent Healthcare Approvals Brand ing Brand Institute is the world’s premier brand identity consultancy. Our brand agency portfolio of services includes brand strategy/architecture, name development, market research, regulatory and visual identity solutions.

Jan 14 2018

Shionogi – Co, Ltd, shionogi pharma.#Shionogi #pharma

Mother to Mother (SHIONOGI Project) SHIONOGI Science Program 2017 Copyright (C) Shionogi Co., Ltd. All Rights Reserved.

Dec 26 2017

Shionogi Pharmaceutical Research Facility, Osaka – Pharmaceutical Technology #pharmaceutical #company #list

#shionogi pharma # Shionogi Pharmaceutical Research Facility, Osaka, Japan Project Type Pharmaceutical Research Facility Location Toyonaka, Osaka Construction Commenced September 2008 Completed July 2011 Operations Started August 2011 Investment ¥18.9bn ($247m) Owner Shionogi & Co Shionogi Co’s new pharmaceutical research facility is located in Toyonaka City in Osaka, Japan. The new facility was opened in August 2011. It is equipped with drug discovery research laboratories and laboratory equipment, as well as information technology capabilities. The new facility was built with an investment of about ¥18.9bn ($247m). It will serve as the main research facility for Shionogi. With the construction of …

Dec 26 2017

Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharmacy #online

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …

Dec 1 2017

Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharma #chemie

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …

Dec 1 2017

Shionogi Pharma Media and Investor Relations – Investor Relations #pharmaceutical #industry #marketing

#shionogi pharma # Investor Relations About Shionogi Pharma, Inc. Shionogi Pharma, Inc. (formerly Sciele Pharma, Inc.), is a US-based group company of Shionogi & Co. Ltd, based in Atlanta, Georgia specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women’s Health and Pediatrics. The Company’s Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and type 2 diabetes; its Women’s Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, head lice infestations, and attention deficit/hyperactivity disorder (ADHD). About …

Nov 24 2017

Shionogi Inc #chugai #pharma

#shionogi pharma # Shionogi Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? Drugs.com …

Nov 14 2017

Lupin Acquires Branded Product Portfolio from Shionogi in Japan #jobs #in #pharmaceuticals

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …

Nov 14 2017

Shionogi Inc #diamond #pharma

#shionogi pharma # Shionogi Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? Drugs.com …

Oct 6 2017

Shionogi Inc #cadila #pharma

#shionogi pharma # Shionogi Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? Drugs.com …